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ADAM17/EGFR axis promotes 
transglutaminase-dependent 
skin barrier formation through 
phosholipase C γ1 and protein 
kinase C pathways
Cristina Wolf 1,*,†, Yawen Qian1,*, Matthew A. Brooke2, David P. Kelsell2  
& Claus-Werner Franzke1
The vitally important skin barrier is formed by extensive cross-linking activity of transglutaminases 
(TGs) during terminal epidermal differentiation. We have previously shown that epidermal deficiency 
of a disintegrin and metalloproteinase 17 (ADAM17), the principal EGFR ligand sheddase, results 
in postnatal skin barrier defects in mice due to impeded TG activity. However, the mechanism by 
which ADAM17/EGFR signalling maintains TG activity during epidermal differentiation remains 
elusive. Here we demonstrate that ADAM17-dependent EGFR signalling promotes TG activity in 
keratinocytes committed to terminal differentiation by direct induction of TG1 expression. Restored 
TG1 expression of EGF-stimulated differentiated Adam17−/− keratinocytes was strongly repressed 
by inhibitors for PLCγ1 or protein kinase C (PKC) pathways, while treatment with the PKC stimulator 
12-O-tetradecanoylphorbol-13-acetate restored TG activity in the epidermis of keratinocyte-specific 
Adam17−/− (AD17ΔKC) mice. Further investigations emphasized the expression of PKCη, a mediator 
of TGM1 transcription, to be sensitive to EGFR activation. In agreement, topical skin application of 
cholesterol sulfate, an activator of PKCη, significantly improved TG activity in epidermis of AD17ΔKC 
mice. Our results suggest ADAM17/EGFR-driven PLCγ1 and PKC pathways as important promoters of 
TG1 expression during terminal keratinocyte differentiation. These findings may help to identify new 
therapeutic targets for inflammatory skin diseases related to epidermal barrier defects.
The multilayered epidermis builds up a barrier that protects the body against transepidermal water loss, foreign 
substances and microbial invasion1. This skin barrier is very important for the epidermal homeostasis and needs 
to be continuously renewed and enzymatically modified2. After the basal keratinocytes detach from the underly-
ing basement membrane, they stop to proliferate and become committed to terminal differentiation. During their 
passage to the skin surface the cells convert into a cornified envelope (CE) that forms the skin barrier. The CE 
represents an insoluble protein structure that is stabilized by the cross-linking activity of three epidermal trans-
glutaminases (TGs), namely TG1, TG3 and TG53. However, lack of either TG3 or TG5 activity only leads to minor 
alterations in CE formation and barrier stability4,5, while lack of TG1 activity causes severe skin barrier defects. 
The crucial role of TG1 during CE formation is demonstrated in patients with nonsense or missense mutations 
in the TGM1 gene, that led to impaired skin barrier formation, transepidermal water loss and skin inflammation 
in autosomal recessive lamellar ichthyosis or congenital ichthyosiform erythroderma3,6. However the regulatory 
mechanisms that control TG activity during skin barrier maintenance remain elusive.
In the epidermis, epidermal growth factor receptor (EGFR) is expressed abundantly in the proliferative basal 
layer and to a lesser degree in the differentiating suprabasal layers7. It is thought that EGFR signalling in basal 
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keratinocytes mainly supports proliferation and survival but prevents differentiation. Moreover it delays apop-
tosis during early differentiation in suprabasal keratinocytes that have lost their interaction with the matrix8,9. 
However, EGFR-ligands are also abundant in differentiated epidermis and there are several evidences that EGFR 
signalling contributes to terminal keratinocyte differentiation and skin barrier formation10–13. EGFR deficiency 
causes defects in hair follicle development and immature epidermal differentiation with inflammatory skin reac-
tions in both mice and humans14–17. In addition, EGFR inhibitor therapy in cancer patients commonly induces 
dermatologic side effects including xerotic itchy skin18. Although these data corroborate the relevance of EGFR 
signalling in skin homeostasis, only little is known about the role of EGFR signalling in skin barrier formation 
and in suppressing chronic skin inflammation.
ADAM17 (a disintegrin and metalloproteinase 17) or tumor necrosis factor α -converting enzyme (TACE) is a 
membrane-anchored metalloproteinase that was originally identified to cleave membrane-bound tumor necrosis 
factor (TNF)-α by a process named as ectodomain shedding19. This protease is also known as crucial upstream 
regulator of EGFR signalling by shedding of the majority of EGFR ligands20. Mice lacking ADAM17 die at birth 
due to defects in heart development and show epithelial abnormalities in several organs, such as intestine and 
skin21. Thereby, Adam17−/− mice nearly phenocopy mice lacking EGFR, or mice lacking the EGFR ligands TGF-α 
, HB-EGF, or amphiregulin (AREG), indicating an in vivo relevance of ADAM17 in EGFR signalling22.
To investigate the role of ADAM17 and EGFR in skin homeostasis, mice with a conditional 
keratinocyte-specific deletion were generated. Adam17ΔKC (AD17ΔKC) mice phenocopy EgfrΔKC mice in having 
an intact skin barrier at birth, but developing a pronounced defect in the skin barrier after the third postnatal 
week leading to more than 80% lethality. The surviving animals develop chronic dermatitis as adults13,16,23. During 
the last five years several patients with germline loss of function mutations in ADAM17 or EGFR have been 
described17,24,25, which developed chronic dermatitis with iterated skin infections, very similar to the phenotype 
of AD17ΔKC mice, which suggests similar skin barrier defects13,23. Our investigations on AD17ΔKC and EgfrΔKC 
mice revealed that ADAM17/EGFR axis sustained the CE formation and postnatal skin barrier stability by tightly 
regulation of the expression and proteolytic processing of several CE components, especially by supporting TG 
activity13,26. Accordingly, application of EGFR ligand TGF-α to AD17ΔKC mouse skin restored epidermal barrier 
integrity by stimulating skin TG activity13. However, the ADAM17-driven mechanisms that maintain epidermal 
TG activity during terminal differentiation are not well understood.
Here we demonstrate that ADAM17-dependent EGFR signalling directly induces TG1 expression in keratino-
cytes committed to terminal differentiation prominently through phospholipase C γ 1 (PLCγ 1) and protein kinase 
C (PKC) pathways. Further investigations identified PKCη expression to be responsive to EGFR activation. In 
agreement, topical skin application of cholesterol sulfate, an activator of PKCη , significantly improved TG activity 
in epidermis of AD17ΔKC mice. These findings will help to uncover novel therapeutic strategies for inflammatory 
skin diseases related to disrupted EGFR signalling.
Results
ADAM17-driven EGFR signalling induces expression and activity of TG1 in terminal differen-
tiating keratinocytes. The TG activity in terminal differentiating keratinocyte is composed of activities 
derived from TG1, TG3 and TG52. We previously demonstrated that lack of Adam17 in differentiated murine 
keratinocytes leads to significantly reduced TG activity and decreased expression of TG1 and TG313 as well as 
reduced Tgm5 transcription (data not shown). These findings suggest that ADAM17 controls TG activity by 
modulation of all epithelial TGs. However, lack of either TG3 or TG5 activity causes, if at all, only minor barrier 
defects4,5, while lack or strongly reduced TG1 activity leads to severe barrier defects3,6 as seen in AD17ΔKC mice. 
Therefore, we focused our investigations on TG1 expression and activity.
For the determination of TG1 activity we analyzed skin cryo sections or culture cells on coverslips in situ 
using the biotinylated amine donor substrate monodansylcadaverine in a neutral pH 7.4 buffer system, in which 
TG3 and TG5 are not active5,27. It has been previously demonstrated that this in situ fluorescence technique can 
discriminate among the activities of TG1 and TG3/TG5 when performed either at neutral pH 7.4 or at basic pH 
8.4, respectively. This based on the fact that the catalytic optimum of TG1 lies between pH 7.4 and pH 8.4, while 
the catalytic optimum for TG3 and TG5 lies at basic pH 8.427,28. To investigate how the ADAM17-dependent 
EGFR signalling regulates TG activity in keratinocytes committed to differentiation, we used suspension cultures 
on polyhydroxyethylmethacrylate (polyHEMA)-coated plates10. This system mimicks terminal differentiation of 
suprabasal epidermal keratinocytes, since it disrupts the cell-extracellular matrix interaction, while maintaining 
cell-cell interactions. Time-resolved analysis of the TG activity in polyHEMA cultured wild type keratinocytes 
revealed strong activity after 6 h, which was retained for at least 48 h (Supplementary Fig. S1a). This correlated 
with a strong increase in transcription of the genes encoding for TG1 or involucrin (Supplementary Fig. S1b). 
Since permanent cell cycle exit and commitment to terminal differentiation of keratinocytes occurred within the 
first 24 h of suspension culture29, we have used 24 h suspension culture in our following experiments.
Analysis of EGFR signalling in Adam17−/− keratinocytes by Western blot (WB) revealed about 80% reduced 
EGFR activation (Fig. 1a). To validate whether the reduced TG activity is caused by lack of EGFR signalling, 
we analyzed 24 h suspension cultures of Egfr−/− keratinocytes. Indeed, Egfr−/− keratinocytes showed strongly 
reduced TG activity (Fig. 1b). In addition, the reduced TG1 expression in ECM-disrupted Adam17−/− keratino-
cytes was nearly restored by supplementation with the EGFR-ligand TGF-α (40 ng/ml) on protein (Fig. 1c) and 
on RNA level (Supplementary Fig. S2), suggesting that the lack of EGFR activation is the major cause of reduced 
TG1 expression in Adam17−/− keratinocytes. Since reduced EGFR signalling in the suprabasal Adam17−/− kerat-
inocytes can lead to decreased survival signals and apoptosis30, we analyzed skin sections of 10-day-old AD17ΔKC 
mice with skin barrier defects and their littermates by TUNEL labelling. No difference in the proportion of 
TUNEL-positive keratinocytes was detectable (Supplementary Fig. S3), indicating no increase of apoptosis in 
the epidermis of AD17ΔKC mice. Moreover, supplementation of the EGFR-ligands EGF, TGF-α , and Epiregulin 
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(40 ng/ml) to 24 h Adam17−/− keratinocyte suspension cultures resulted in very similar recovery of TG activity 
(Supplementary Fig. S4), suggesting coinciding functions among these EGFR-ligands. These results suggest that 
EGFR signalling accelerates TG activity in differentiating keratinocytes via transcription.
PKC regulates TG1 expression downstream of EGFR. The terminal differentiation of keratinocytes 
is partly regulated by PKC31. These kinases are thought to play an important role in the modulation of trans-
glutaminase activity32–34. However, only little is known about the interactions of EGFR and PKC pathways in 
keratinocytes committed to terminal differentiation. To analyse the interactions of both pathways, we used 
TGFα -stimulated differentiated Adam17−/− keratinocytes as a model for EGFR-dependent TG activity. Addition 
of the general PKC inhibitor bisindolylmaleimide (1 μ M) led to strongly reduced TG activity and TG1 expression 
in TGFα -stimulated differentiated Adam17−/− keratinocytes (Fig. 2a,b), suggesting a connection of both path-
ways in the regulation of TG expression and that PKCs are localized downstream of ADAM17/EGFR signalling. 
These results were confirmed by stimulation experiments with the phorbol ester 12-O-tetradecanoylphorbol-
13-acetate (TPA), a strong PKC activator. Stimulation of 24 h suspension cultures with 1 μ M TPA completely 
restored the TG activity in differentiating Adam17−/− keratinocytes (Supplementary Fig. S5a). WB analysis 
revealed significantly increased TG1 expression in these cells (Supplementary Fig. S5b), suggesting a transcrip-
tional regulation. To further validate the in vivo relevance of our results, we used 10 days old keratinocyte-specific 
Adam17−/− mice (A17ΔKC) with strongly reduced epidermal TG activity13 and topically applied a single dose 
of 1.5 μ g TPA in acetone or acetone vehicle alone (controls) on their back skin. TPA treatment for 6 h resulted 
Figure 1. Transglutaminase activity in differentiating mouse keratinocytes is regulated by EGFR 
signalling. (a) WB of primary keratinocyte lysates derived from AD17∆KC mice or control littermates (Ctrl) 
revealed significantly reduced level of activated EGFR (normalized ratio of pEGFR/total EGFR), while ERK 
2 protein as control was equal. Graph shows band intensities as mean ± SD, n = 3, **p < 0.01. (b) Suspension 
cultured Egfr−/− keratinocytes analyzed for TG activity at pH 7.4 by fluorescence microscopy revealed strongly 
reduced signals (white arrows, scale bar, 20 μ m) (representative staining from three independent experiments). 
(c) WB analysis of mouse AD17−/− keratinocytes with or without stimulation with 40 ng/ml TGF-α after 24 h 
suspension culture with antibodies directed against TG1. (n = 3 per group). Data as mean ± SEM, **p < 0.01, 
***p < 0.001.
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in strongly improved TG activity in the epidermis (Fig. 2c). In contrast, TPA treatment for 1 h did not led to 
improved TG activity (data not shown). In summary, our results demonstrate that the ADAM17/EGFR axis reg-
ulates TG1 expression during terminal keratinocyte differentiation via PKCs.
ADAM17/EGFR axis induces TG activity mainly through PLCγ1 and PKC pathways. To identify 
the pathways by which the ADAM17/EGFR axis regulates TG activity in keratinocytes during terminal differen-
tiation we have analyzed the MAPK, PI3K/Akt and PLC/PKC signalling as well known EGFR downstream path-
ways9,35. WB analysis of lysates of epidermis splits derived from 10 day old AD17ΔKC mice with strongly decreased 
TG activity13 revealed significant reduced activation of the PLCγ 1 pathway, but no changes in ERK1/2 and Akt 
activation (Fig. 3a). The reduction in PLCγ 1 signalling was verified as a cell-autonomous mechanism, since it was 
also detected in differentiation-committed Adam17−/− keratinocytes (Fig. 3b). In addition, we also saw reduced 
ERK1/2 signalling in these cells (Fig. 3b), suggesting that the ERK pathway might be involved as well. The PLCγ 1 
and the ERK1/2 signalling was strongly induced by EGF stimulation of 24 h Adam17−/− keratinocyte suspension 
cultures, validating the responsiveness of both pathways in differentiation-committed keratinocytes (Fig. 3c). 
Figure 2. Protein kinase C (PKC) in murine keratinocytes regulates TG1 expression & activity downstream 
of EGFR in vitro and in vivo. (a,b) Mouse wild type and Adam17−/− keratinocytes were cultured in suspension 
for 24 h. Adam17−/− keratinocytes were either treated with 40 ng/ml TGF-α or 40 ng/ml TGF-α and 1 μ M 
bisindolylmaleimide (BIM) and then analyzed by (a) in situ TG activity detection at pH 7.4 by fluorescence 
microscopy or (b) WB with antibodies against TG1 and ERK as control. The improved TG1 expression and 
activity of TGF-α stimulated Adam17−/− keratinocytes was strongly inhibited by 1 μ M bisindolylmaleimide. 
Scale bar, 20 μ m. Graph shows band intensities as mean ± SEM, n = 3, **p < 0.01, ***p < 0.001. (c) The phorbol 
ester TPA was topically applied on the shaved skin surface of 10 days old AD17ΔKC mice (P10) and the skin was 
analyzed for in situ TG activity at pH 7.4 after 6 h. Scale bar, 50 μ m. TPA treatment resulted in strongly improved 
TG activity (representative staining from three independent experiments).
www.nature.com/scientificreports/
5Scientific RepoRts | 6:39780 | DOI: 10.1038/srep39780
Using EGF-stimulated differentiated Adam17−/− keratinocytes as a model for EGFR dependent TG activity, the 
addition of either the PLC inhibitor U73122 or the general PKC inhibitors bisindolylmaleimide or Gö6983 (data 
not shown) strongly repressed TG activity. However, the addition of the selective PI3K inhibitor Ly294002 or 
Figure 3. The PLCγ1 pathway is downregulated in murine Adam17−/− keratinocytes. (a,b) Representative 
WBs of (a) epidermal splits derived from P10 AD17∆KC or wild type mice or (b) 24 h suspension cultured wild 
type and Adam17−/− keratinocytes for activation of PLCγ 1, ERK and Akt pathways. The graphs on the right 
show the mean ± SD of the relative intensities of pPLCγ 1/PLCγ 1, pERK/ERK and pAkt/Akt (n = 3), *p < 0.05. 
The activation of the PLCγ 1 pathway was significantly reduced in AD17∆KC epidermis as well as Adam17−/− 
keratinocytes. (c) After suspension culture for 24 h, Adam17−/− keratinocytes were treated with 40 ng/ml EGF 
or vehicle for additional 30 min and analyzed by WB for activation of PLCγ 1 and ERK. Both, pPLCγ 1 and pERK 
were strongly increased by EGF stimulation (representative blots of three independent experiments).
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the selective MEK1 and MEK2 inhibitor PD98059 led to partial inhibition of TG activity in these cells (Fig. 4a). 
Further analysis of TG1 expression of those cells by WB revealed very similar results (Fig. 4b). In conclusion, 
these results suggest that especially the PLCγ 1 and PKC pathways are involved in the regulation of TG activity in 
differentiation-committed keratinocytes.
Expression of PKCη, but not PKCδ is responsive to EGFR/PLCγ1 signalling. The expression of 
three protein kinase C members, namely PKCα , PKCδ and PKCη , has been linked to epidermal terminal differen-
tiation36,37. However, only PKCδ and PKCη seem to be involved in the induction of TG1 activity and expression37. 
To further understand which of the epidermal PKC isoforms are directly affected by absence of ADAM17/EGFR 
signalling, we investigated their expression in AD17ΔKC versus wild type mice by WB analysis. Interestingly, we 
found significantly reduced expression of PKCη in Adam17−/− epidermal splits as well as in ECM-disrupted 
Figure 4. EGFR induced TG activity in murine Adam17−/− keratinocytes is mainly driven by PLCγ1 and 
PKC signalling. (a) Murine Adam17−/− keratinocytes were cultured in suspension on poly-HEMA for 24 h in 
the presence of 40 ng/ml EGF and either DMSO (vehicle control), 50 μ M Ly294002, 1 μ M bisindolylmaleimide 
(BIM), 50 μ M PD98059, or 5 μ M U73122. Afterwards, the keratinocytes were analyzed for TG activity at pH 
7.4 by fluorescence microscopy. The addition of either the PLC inhibitor U73122 or the general PKC inhibitor 
bisindolylmaleimide completely decreased EGF-induced TG activity in Adam17−/− keratinocytes, while 
addition of the selective PI3K inhibitor Ly294002 or the selective MEK1 and MEK2 inhibitor PD98059 caused 
partially inhibition. (n = 4). Scale bar, 20 μ m. Graph shows quantitative analysis of fluorescence intensities: 
mean ± SEM, *p < 0.05, ***p < 0.001. (b) WB analysis of cell lysates from the in (a) treated Adam17−/− 
keratinocytes with antibodies against TG1. β -actin was used as loading control (representative blots of two 
experiments).
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differentiated Adam17−/− keratinocytes. In contrast, no changes were observed for PKCδ (Fig. 5a,b) or PKCα 
(data not shown). The reduced PKCη expression in differentiation-committed Adam17−/− keratinocytes was sig-
nificantly induced by stimulation with EGF, while PKCδ expression was not affected (Fig. 5c). This result was 
also seen in wild type keratinocytes (Supplementary Fig. S6), indicating that PKCη expression is modulated by 
EGFR signalling. The linkage of PLCγ 1 signalling and PKCη expression was assessed by treatment of wild type 
or Adam17−/− keratinocyte suspensions with the PLC inhibitor U73122. Supplementation of 5 μ M U73122 led 
to dramatically decreased protein expression of PKCη and TG1 in wild type and Adam17−/− keratinocytes, while 
the expression PKCδ was not altered (Fig. 5d). To further confirm the role of PKCη in the modulation of TGs, 
wild type ECM-disrupted keratinocytes were cultivated for 24 h in the presents of selective inhibitors for either 
PKCδ or PKCη . The selective myristoylated pseudosubstrate inhibitor (Myr-TRKRQRAMRRRVHQING-OH) 
for PKCη caused a significant reduction in TG activity. In contrast, rottlerin, a selective PKCδ inhibitor, had no 
effect on TG activity (Supplementary Fig. S7). Taken together, these results suggest that EGFR/PLCγ 1 signalling 
is involved in the induction of PKCη expression, which in turn leads to increased TG1 expression and activity.
Cholesterol-sulfate supplementation restores TG activity in Adam17−/− keratinocytes in vitro 
and in vivo. The membrane lipid cholesterol sulfate is thought to play an important role in the physiological 
induction of epidermal terminal differentiation and skin barrier formation. Cholesterol sulfate is constitutively 
produced in the suprabasal epidermal layers where it progressively accumulates during terminal differentiation. 
It has previously been shown in vitro that stimulation of adhesive keratinocytes with cholesterol sulfate leads to 
increased expression of terminal differentiation markers, including TG1. This effect is mediated via PKC activity, 
in which cholesterol sulfate acts as a more specific activator of novel PKCs, especially PKCη 38–40.
To investigate whether cholesterol sulfate can increase TG activity in Adam17−/− keratinocytes, we analyzed 
either the addition of 5 or 20 μ M cholesterol-3-sulfate to suspension cultures. Stimulation of 24 h suspension cul-
tures completely restored the TG activity in the Adam17−/− keratinocytes in a dose dependent manner (Fig. 6a). 
However, WB analysis revealed no increase in PKCη expression in these cells (data not shown), suggesting 
an induction in kinase activity. To further validate the in vivo relevance of our results, we treated 10 days old 
AD17ΔKC mice by a single topically application of 100 μ g cholesterol-3-sulfate or acetone vehicle (controls) on 
their back skin. Cholesterol sulfate treatment for 6 h was sufficient to restore the TG activity in the epidermis of 
AD17ΔKC mice (Fig. 6b), indicating a therapeutic value of local cholesterol sulfate administration.
Reduced TG activity in ADAM17-deficient human skin. After the discovery of the first two ADAM17 
deficient patients with inflammatory skin and bowel disease in 201124, additional pediatric patients with deficien-
cies in ADAM17 or EGFR were described17,25. All of these patients suffered of skin inflammation and iterated skin 
infections, very similar to the phenotype of keratinocyte-specific Adam17−/− mice, which suggests similar skin 
barrier defects13,23. However, the TG activity in the skin of these patients was not evaluated. Thus, we analyzed 
skin cryo sections derived from an ADAM17-deficient patient or healthy donors by in situ immunofluorescence 
microscopy using biotinylated monodansylcadaverine at neutral pH 7.4. As shown in Fig. 7, the TG activity in 
the stratum granulosum and stratum corneum of the epidermis was strongly reduced in ADAM17 deficient skin 
compared to control skin. Therefore, we conclude that the mechanisms of the loss of transglutaminase activity 
due to ADAM17-deficiency are very similar in human and mouse skin.
Discussion
Using epidermis-specific conditional Adam17 or Egfr knockout mice, we have previously shown that lack of 
ADAM17-dependent EGFR ligand shedding in keratinocytes leads to postnatal skin barrier defects due to 
decreased TG activity13,26. Here, we provide new insights into the downstream mechanisms and demonstrate that 
ADAM17-driven EGFR signalling directly promotes TG1 expression and activity in keratinocytes committed to 
differentiation mainly via PLCγ 1 and PKC pathways. At first glance our results seem to be in direct conflict with 
previously published data, which showed EGFR-dependent repression of TGM1 transcription in keratinocytes 
due to induced production of the transcription factor homeobox protein A7 (HOXA7)41. However, these results 
derived from adherent, proliferative cells that strongly express HOXA7, while its expression is lost in terminal 
differentiated keratinocytes due to enhanced PKC signalling41. Thus, our results emphasize the difference in the 
biological effect of EGFR signalling in delaminated terminal differentiating keratinocytes, where it promotes 
terminal differentiation via induction of TG1 expression and activity. In agreement, a constitutive increase of 
ADAM17-driven EGFR signalling was observed in tylosis (TOC) keratinocytes42. TOC is an autosomal dominant 
syndrome with focal palmoplantar keratoderma and esophageal cancer due to autosomal dominant iRHOM2 
mutations43. TOC skin also shows epidermal hyperproliferation and hyperkeratosis with elevated epidermal TG 
activity42.
EGFR signalling in basal membrane anchored keratinocytes promotes proliferation and survival via the ERK 
and Akt pathways, but not via PLCγ 19. In contrast, PLCγ 1 signalling is proposed to lead to terminal keratinocyte 
differentiation through activation of PKCs44,45. Our data provides the novel finding that the ADAM17/EGFR axis 
in terminal differentiating keratinocytes mainly promotes PLCγ 1 signalling. Although PLCγ 1 activation by direct 
membrane recruitment to EGFR has been shown in several cell systems46,47, no such activation has been demon-
strated so far in keratinocytes48. The increased cholesterol production and membrane integration during terminal 
keratinocyte differentiation seems to have an important impact on the morphological cell changes and the lipid 
raft-mediated signalling49. Therefore it is very likely that this increase in lipid microdomains leads to enriched 
EGFR cell surface localization in differentiation-committed keratinocytes, which in turn facilitates cell surface 
recruitment of PLCγ 1 and EGFR/PLCγ 1 signalling50. Upon membrane recruitment and activation, PLCγ 1 catal-
yses the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5-trisphosphate (IP3) and dia-
cylglycerol (DAG), which both act as second messengers in the activation of PKCs in terminal differentiation44. 
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Figure 5. Expression of PKCη but not PKCδ is enhanced by EGFR-PLCγ1 signalling in murine epidermis. 
(a,b) WB analysis of (a) epidermal splits derived from P10 AD17∆KC or wild type mice or (b) lysates derived 
from 24 h suspension cultured mouse wild type and Adam17−/− keratinocytes with antibodies against PKC 
isoforms eta or delta, and β -actin as loading control. The graphs below show the mean ± SD of the signal 
intensities (n = 5), *p < 0.05; **p < 0.01. The expression of PKCη was significantly reduced in Adam17−/− 
keratinocytes in vivo and in vitro. (c) Adam17−/− keratinocytes were suspension-cultured on poly-HEMA 
with or without 40 ng/ml EGF for 24 h and further analyzed by WB for PKC isoforms eta or delta and ERK as 
loading control. Graph on the right shows quantitative analysis of band intensities as mean ± SEM, *p < 0.05. 
PKCη expression in Adam17−/− keratinocytes was significantly induced by stimulation with EGF, while PKCδ 
expression was unchanged. (d) Wild type or Adam17−/− keratinocytes were suspension-cultured for 24 h 
with or without addition of 5 μ M U73122 and further analyzed by WB for TG1, PKC isoforms eta or delta. 
Antibodies against β -actin were used as loading control. Graph on the right shows quantitative analysis of band 
intensities normalized to controls (n = 3): mean ± SEM, **p < 0.01; ***p < 0.001. The supplementation of 5 μ 
M U73122 led to dramatically decreased protein expression of PKCη and TG1 in wild type and Adam17−/− 
keratinocytes, while the expression PKCδ was not affected. Full-length blots of (b) and (d) are presented in 
Supplementary Fig. S8.
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Thus, our data suggest that EGFR signalling stabilizes terminal differentiation by maintenance of PKC activity in 
differentiation-committed keratinocytes via PLCγ 1 activation.
In vitro studies revealed that lack of EGFR/ERK signalling in suspension cultured keratinocytes for more than 
24 h can lead to apoptosis due to the loss of basement membrane interactions30, which could be the reason for 
decreased activity and expression of TG1 in Adam17−/− keratinocytes. Although we used a different suspension 
culture system than the authors and cultured the cells for a maximum of 24 h under EGF supplementation, we 
saw reduced ERK activation in Adam17−/− keratinocytes. However, we neither detected decreased ERK signalling 
nor increased apoptosis as determined by TUNEL labelling in the epidermis of AD17ΔKC mice, which questions 
the in vivo relevance of the above findings. Furthermore, it has been demonstrated that PKCs can be involved 
in the activation of ERK signalling51,52. Thus, reduced PKC signalling might cause decreased ERK activation in 
Adam17−/− keratinocytes.
Our results suggest that ADAM17-driven EGFR signalling in differentiated keratinocytes acts in two dif-
ferent ways to induce PKC signalling and promote TG1 activity. Firstly, it activates PLCγ 1 that produces sec-
ond messengers for the activation of keratinocyte-derived PKC isoforms, namely the classical calcium- and 
diacylglycerol-dependent PKCα and the novel calcium-independent but diacylglycerol-dependent PKCδ , PKCε 
and PKCη 31. Secondly, it selectively induces the expression of PKCη . This result is of particular interest, since only 
little is known about the transcriptional control of the novel PKCs during terminal differentiation. The induction 
of PKCη expression is probably driven via EGFR/PLCγ 1 signalling, since PKCη expression was highly sensitive 
to PLCγ 1 inhibition. However, it can not be ruled out that other signalling pathways are involved as well. PKCη 
is strongly linked to terminal keratinocyte differentiation, since it is selectively expressed in suprabasal epidermal 
layers and its viral overexpression in adherent human keratinocytes caused growth inhibition and induction of 
TG1 expression and activity37,39,53. However, PKCη activity seems not to be crucial for epidermal differentiation 
Figure 6. Cholesterol sulfate supplementation increased TG activity in murine keratinocytes in vivo and 
in vitro. (a) Mouse Adam17−/− keratinocytes were cultured in suspension and stimulated with either 5 μ M or 
20 μ M cholesterol-3-sultate for 24 h. Analysis of TG activity at pH 7.4 by fluorescence microscopy. TG activity 
of wild type keratinocytes is shown as control. n = 3. Scale bar, 20 μ m. Graph shows fluorescence intensities as 
mean ± SEM, **p < 0.01, ***p < 0.001. Cholesterol sulfate stimulation resulted in a dose-dependent increase of 
TG activity in differentiating Adam17−/− keratinocytes. (b) Cholesterol sulfate (100 μ g/20 μ l) or 20 μ l acetone-
vehicle (control) was topically applied on the shaved skin surface of 10 days old AD17ΔKC mice (P10) and 
the skin was analyzed for in situ TG activity at pH 7.4 after 6 h. Untreated skin of wild type mice was used as 
positive control. Fluorescence microscopy analysis revealed strongly improved TG activity by cholesterol sulfate 
treatment (representative images of three independant experiments). Scale bar, 50 μ m.
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in normal skin and is most likely replaceable by other PKC isoforms, since PKCη null mice showed no defects in 
skin architecture and development54.
Taken together, our data suggest ADAM17/EGFR-driven PLCγ 1 and PKC pathways as important promoters 
of TG1 expression during terminal keratinocyte differentiation and skin barrier formation. It further provides 
evidence that topical skin application of TPA or cholesterol sulfate can restore the TG activity in the epider-
mis of AD17ΔKC mice, which should have a beneficial effect on the skin barrier function. In contrast to the 
tumor-promoting phorbol ester TPA, that activates almost all PKCs, cholesterol sulfate is a more specific activator 
of novel PKCs, especially PKCη , and rather acts as an anticarcinogenic component38–40. Thus, cholesterol sulfate 
seems to have therapeutic value for the local treatment of disrupted EGFR signalling caused skin barrier defects 
in atopic dermatitis55 or EGFR inhibitor-treated cancer patients18.
Methods
Material. The PI3K inhibitor Ly294002 was purchased from Merck Millipore (Germany) and the 
ERK1/2 inhibitor PD98059 derived from Cell signalling technology (Germany). The general PKC inhibi-
tors Bisindolylmaleimide and Gö6983 were obtained from Sigma-Aldrich (Germany) and Merck Millipore 
(Germany), respectively. Rottlerin, a selective inhibitor of PKCδ was obtained from Sigma-Aldrich (Germany) 
and the PKCη pseudosubstrate inhibitor, myristoylated (Myr-TRKRQRAMRRRVHQING-OH) was bought from 
Merck Millipore. Recombinant murine EGF, human TGF-α and human Epiregulin were obtained from Peprotech 
(Germany).
Animals. The generation of Adam17flox/flox Krt14-Cre (AD17ΔKC) and Egfrflox/flox Krt14-Cre (EgfrΔKC) mice 
has been described previously13. All mice were of mixed genetic background (129 Sv, C57BL/6), and all com-
parisons were between littermates. In experiments, mice received a single 100 μ l application of either 1.5 μ g 
12-O-tetradecanoylphorbol-13-acetate (TPA, Sigma-Aldrich) or 100 μ g cholesterol 3-sulfate (Sigma-Aldrich) in 
acetone or acetone vehicle on the shaved back skin. The mice were maintained in the Center for Experimental 
Models and Transgenic Service (CEMT) of the Medical Center University of Freiburg, and all experiments 
were performed according to the guidelines of the German Animal Welfare association and approved by the 
Regierungspräsidium Freiburg (G-11/98 and G-15/145).
Figure 7. Lack of ADAM17 in humans is associated with decreased epidermal TG activity. In situ detection 
of TG activity in skin sections at pH 7.4 derived from an ADAM17 deficient patient24 and healthy volunteers 
by fluorescence microscopy. The TG activity in the stratum granulosum and stratum corneum of the epidermis 
was strongly reduced in ADAM17 deficient skin compared to control skin (representative images of three 
independant experiments). Scale bars, 100 μ m.
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Primary keratinocyte preparation and cultivation. Keratinocytes were isolated from the skin of neo-
natal AD17ΔKC mice and their wild type littermates as described previously56. The primary cells were cultured 
in defined serum-free keratinocyte growth medium (CellnTec, Switzerland) supplemented with 100 U/ml pen-
icillin, 100 μ g/ml streptomycin (Invitrogene). The cells were maintained at 37 °C, 5% CO2 and 95% humidity. 
Keratinocytes derived from passages 1–2 were used for the experiments.
Keratinocyte suspension culture. Suspension culture on poly (2-hydroxyethyl methacrylate (HEMA))–
coated plates was performed as previously described10. 6-well or 12-well plates were coated with either 10 mg 
or 4 mg poly-HEMA (Sigma-Aldrich) respectively, followed by extensive PBS washes. 1 × 106 or 0,5 × 106 cells 
in keratinocyte growth medium (CellnTec, Switzerland) were added to each coated 6-well or 12-well respec-
tively and incubated in a humidified incubator with 5% CO2 in air at 37 °C for 24 h. EGFR stimulations were 
performed with either 30 ng/ml EGF, TGFα or Epiregulin. In some experiments, the cell suspensions were sup-
plied with 500 nM GÖ 6983, 1 μ M bisindolylmaleimide, 50 μ M Ly294002, 50 μ M PD98059, or 5 μ M U73122 for 
24 h. Cell suspensions were harvested by centrifugation and either used for preparation of cell lysates or detec-
tion of TG activity. For in vitro TG activity detection, 24-h suspension-cultured keratinocytes were attached on 
gelatin-coated coverslips for 1 h and TG activity was determined as described below.
Quantitative RT-PCR analysis. Total RNA from suspension-cultured Adam17−/− and wild type kerati-
nocytes was extracted using RNeasy kit (Qiagen). 1 μ g of total RNA was reverse transcribed using a First Strand 
cDNA Synthesis kit (Fermentas). Relative quantification of gene expression was performed by real-time quantita-
tive PCR using iQ SYBR-Green Supermix on the CFX96TM C1000TM Thermal Cycler (Bio-Rad, Germany) fol-
lowing the manufacturer’s protocols. The used primer sequences for Tgm1, Adam17, Egfr, Inv, Krt14 and Gapdh 
were described previously13. Relative expression was normalized for levels of Gapdh.
Transglutaminase activity assay. For in situ detection of TG activity in skin sections or cells, the biotiny-
lated amine donor substrate monodansylcadaverine (MDC) was used as described earlier13. 5 μ m thick cryostat 
sections were air dried and preincubated with 1% BSA in 0.1 M Tris-HCl, pH 7.4 for 30 min at room tempera-
ture. The sections were then incubated for 45 to 60 min with 100 μ M MDC, 5 mM CaCl2, 0.1 M Tris-HCl, pH 
7.4. After stopping the reaction with 10 mM EDTA and extensive PBS washing, the sections were stained with 
Streptavidin-conjugated Alexa Fluor 488 (Invitrogen) and DAPI-supplemented mounting medium.
Immunoblotting. For WB analysis dispase-separated epidermis splits or cells were homogenized in 50 mM 
Tris-HCl, pH 8.0, 0.15 M NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate supplemented with 2 mM EDTA, 
5 mM 1,10- ortho-phenanthroline (Sigma-Aldrich) and protease inhibitor cocktail set III (Calbiochem) as 
described previously13. Total protein content was determined using the BCATM protein assay kit (Invitrogen). 
30 μ g of protein was separated and transferred either onto nitrocellulose or PVDF membranes. Protein detection 
on membranes was performed with subsequent primary antibodies: rabbit anti-PKCη , rabbit anti PKCδ , rabbit 
anti-transglutaminase 1 (TG1), (Santa Cruz Biotechnology), rabbit anti-PLCγ 1, rabbit anti-phospho PLC-γ 1, 
rabbit anti-EGFR (Cell Signaling), rabbit anti–phospho EGFR (pY1068, clone EP774Y; Epitomics Inc.), rabbit 
anti-ERK1/2, mouse anti-β -actin (Sigma-Aldrich) and mouse anti-GAPDH (Invitrogen). Visualization was per-
formed with secondary horseradish peroxidase labeled goat anti-mouse IgG (Merck) or horseradish peroxidase 
labeled goat anti-rabbit IgG (KPL) and Amersham ECL prime western blotting detection reagent as described by 
the manufacturer (GE Healthcare).
TUNEL assay. The fluorometric DeadEnd™ TUNEL System (Promega) was used to analyze apoptotisis in 
paraffin skin sections (5 μ m) of AD17ΔKC mice and their wild type littermates according the manufacturer´s 
recommendations.
Patient material. Skin samples were obtained from a 17-year-old male ADAM17-deficient patient and 
healthy volunteers undergoing cosmetic surgery after informed consent and in adherence to the declaration of 
Helsinki principles. Clinical details of the ADAM17-deficient patient were described elsewhere24. The study was 
approved by the ethics committee of the Queen Mary University of London.
Statistics. The data are present as mean ± SEM. Data of two groups were analyzed for significance using the 
unpaired Student´s t test and differences are considered to be statistically significant at P < 0.05.
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